Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 1001 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 65 |
| 1002 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 61 |
| 1003 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 65 |
| 1004 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 19 |
| 1005 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 65 |
| 1006 | Apheresis | Allogeneic | Mixed Phenotype Acute Leukemia | Hematology | 2025 | Standard Therapy | Poland | 47 |
| 1007 | Apheresis | Allogeneic | Polycythemia Vera | Hematology | 2025 | Standard Therapy | Poland | 61 |
| 1008 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 56 |
| 1009 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 53 |
| 1010 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 55 |
| 1011 | Apheresis | Allogeneic | Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Hematology | 2025 | Standard Therapy | Poland | 34 |
| 1012 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 50 |
| 1013 | Apheresis | Allogeneic | Myelodysplastic Disorders | Hematology | 2025 | Standard Therapy | Poland | 71 |
| 1014 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | Poland | 64 |
| 1015 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 54 |
| 1016 | Apheresis | Autologous | Non-Hodgkin lymphoma | Hematology | 2025 | Standard Therapy | Germany | 50 |
| 1017 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 50 |
| 1018 | Apheresis | Allogeneic | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 35 |
| 1019 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 54 |
| 1020 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 52 |
| 1021 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 61 |
| 1022 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 55 |
| 1023 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1024 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1025 | Apheresis | Allogeneic | Primary myelofibrosis | Hematology | 2025 | Standard Therapy | Germany | 71 |
| 1026 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 47 |
| 1027 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 1028 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 68 |
| 1029 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Portugal | 44 |
| 1030 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Portugal | 59 |
| 1031 | Apheresis | Autologous | Lymphoma Non-Hodgkin | Hematology | 2025 | Standard Therapy | Portugal | 58 |
| 1032 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Sweden | 59 |
| 1033 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 2 |
| 1034 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 41 |
| 1035 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | France | 48 |
| 1036 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Sweden | 64 |
| 1037 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | United Kingdom | 63 |
| 1038 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | France | 64 |
| 1039 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 58 |
| 1040 | Apheresis | Allogeneic | Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Hematology | 2025 | Standard Therapy | Poland | 68 |
| 1041 | Apheresis | Allogeneic | Myelodysplastic Syndrome, Myeloproliferative Neoplasms | Hematology | 2025 | Standard Therapy | Germany | 59 |
| 1042 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 56 |
| 1043 | Apheresis | Allogeneic | Diffuse Large B-cell Lymphoma | Hematology | 2025 | Standard Therapy | Belarus | 53 |
| 1044 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 60 |
| 1045 | Apheresis | Allogeneic | Immunodeficiency – LRBA | Hematology | 2025 | Standard Therapy | Turkey | 14 |
| 1046 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | Poland | 20 |
| 1047 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 65 |
| 1048 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Ukraine | 54 |
| 1049 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 75 |
| 1050 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 58 |
| 1051 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | Poland | 48 |
| 1052 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 37 |
| 1053 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Chile | 40 |
| 1054 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Germany | 72 |
| 1055 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Switzerland | 65 |
| 1056 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2025 | Standard Therapy | Portugal | 68 |
| 1057 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Estonia | 9 |
| 1058 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2025 | Standard Therapy | USA | 63 |
| 1059 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Sweden | 67 |
| 1060 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Lithuania | 45 |
| 1061 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 59 |
| 1062 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 69 |
| 1063 | Apheresis | Autologous | T-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1064 | Apheresis | Allogeneic | Acute lymphoblastic leukemia | Hematology | 2025 | Standard Therapy | Germany | 42 |
| 1065 | Apheresis | Autologous | Primary central nervous system lymphoma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1066 | Apheresis | Allogeneic | Myelodysplastic Syndrome/ Acute Myeloid Leukemia | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1067 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 42 |
| 1068 | Apheresis | Autologous | T-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 55 |
| 1069 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 72 |
| 1070 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 58 |
| 1071 | Apheresis | Autologous | Central nervous system lymphoma | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 1072 | Apheresis | Autologous | Follicular lymphoma | Hematology | 2025 | Standard Therapy | Germany | 67 |
| 1073 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1074 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 60 |
| 1075 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Portugal | 64 |
| 1076 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Portugal | 63 |
| 1077 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 67 |
| 1078 | Apheresis | Autologous | Acute myeloid leukemia | Hematology | 2025 | Standard Therapy | Germany | 60 |
| 1079 | Apheresis | Autologous | Hodgkin lymphoma rezidiv | Hematology | 2025 | Standard Therapy | Germany | 65 |
| 1080 | Apheresis | Autologous | Non-Hodgkin lymphoma | Hematology | 2025 | Standard Therapy | Germany | 64 |
| 1081 | Apheresis | Autologous | T-cell lymphoma | Hematology | 2025 | Standard Therapy | Germany | 67 |
| 1082 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 70 |
| 1083 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1084 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 62 |
| 1085 | Apheresis | Autologous | Multiple myeloma | Hematology | 2025 | Standard Therapy | Germany | 66 |
| 1086 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | USA | 55 |
| 1087 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Poland | 60 |
| 1088 | Apheresis | Allogeneic | Fanconi’s Anemia | Hematology | 2025 | Standard Therapy | Ukraine | 6 |
| 1089 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | USA | 69 |
| 1090 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | Lithuania | 54 |
| 1091 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Macedonia | 56 |
| 1092 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | CROATIA | 64 |
| 1093 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2025 | Standard Therapy | USA | 75 |
| 1094 | Apheresis | Allogeneic | T-cell Lymphoma | Hematology | 2025 | Standard Therapy | NETHERLANDS | 65 |
| 1095 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2025 | Standard Therapy | Poland | 65 |
| 1096 | Apheresis | Allogeneic | Myeloid Sarcoma | Hematology | 2025 | Standard Therapy | Brazil | 48 |
| 1097 | Apheresis | Allogeneic | T-cell Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 17 |
| 1098 | Apheresis | Allogeneic | Severe Aplastic Anemia | Hematology | 2025 | Standard Therapy | United Kingdom | 13 |
| 1099 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2025 | Standard Therapy | USA | 69 |
| 1100 | Apheresis | Allogeneic | T-cell Acute Lymphoblastic Leukemia | Hematology | 2025 | Standard Therapy | Poland | 13 |